PT Ethica Industri Farmasi (PT EIF), the producer of sterile\ninjectable preparations under PT Pyridam Farma Tbk (PYFA), has completed\nthe expansion of its production capacity for Line 3, which is due to be\ninaugurated in April 2026. At present, Line 3 capacity is already at\nfull capacity, prompting the company to accelerate the development of\nLines 4, 5 and 6.<\/p>\n
Construction of Line 3 began in September 2024 and was completed in\nabout 1.5 years. The acceleration was undertaken to respond to\nincreasing market demand, particularly from hospitals, for injectable\nproducts and sterile dosage forms. The introduction of Line 3 is\ntargeted to increase productivity by up to three times and strengthen\nthe company\u2019s sterile dosage form production capacity.<\/p>\n
In line with the capacity expansion, PT EIF is progressing with the\ndevelopment of Line 4 and Line 5. Line 4 facilities will adopt the\nlatest technology in sterile drug production, which will also be applied\nto Line 5 to ensure product quality and safety is maintained.<\/p>\n
All of these facility expansions are designed with modern production\ntechnology and comply with Indonesia\u2019s current Good Manufacturing\nPractices (cGMP) as well as international standards, PIC\/S, including EU\nGMP requirements and the Australian Therapeutic Goods Administration\n(TGA). These standards are important prerequisites for export market\npenetration and strengthening global competitiveness.<\/p>\n
Following the completion of Lines 4 and 5, the company will continue\nwith the construction of Line 6 as part of its sustainable manufacturing\ncapacity development strategy.<\/p>\n
The expansion comes amid projections of significant growth in the\nglobal sterile injectable market. The global sterile injectable drug\nmarket is expected to reach around US$4.9 billion by 2026 and could rise\nto nearly US$9.9 billion by 2035, with an annual growth rate of about\n8%.<\/p>\n
The Asia-Pacific region is expected to be among the major growth\ndrivers, supported by increases in healthcare spending, expansion of\nmedical service facilities, and a growing need for injectable products\nand sterile dosage forms.<\/p>\n
These trends underscore the importance of having reliable,\nhigh-quality sterile drug manufacturing facilities that meet\ninternational standards to sustain regional supply chains.<\/p>\n
Bejo Stefanus, Director of PYFA, emphasised that developing these\nproduction facilities is part of the company\u2019s long-term strategy. \u2018The\ncompletion of Line 3, which will soon be inaugurated, marks an important\nstep in raising our productivity. The deployment of technology on Lines\n4 and 5 is being undertaken to enhance product quality and safety.\nLooking ahead, the construction of Line 6 will form part of the\ncompany\u2019s commitment to strengthening manufacturing capacity,\u2019 he\nsaid.<\/p>\n
These additions and the development of production lines are believed\nto strengthen PT EIF\u2019s capabilities while boosting PYFA\u2019s\ncompetitiveness in the sterile pharmaceutical industry. The move also\nunderscores the company\u2019s commitment to becoming a leading player in the\nsterile injectables industry at regional and global levels.<\/p>", "url": "https:\/\/jawawa.id\/newsitem\/sterile-injectable-drug-plant-capacity-surges-as-production-line-expansions-accelerated-1772560617", "image": "" }, "sponsor": "Okusi Associates", "sponsor_url": "https:\/\/okusiassociates.com" }